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Abstract
Purpose The second International Consensus Conference on B3 lesions was held in Zurich, Switzerland, in March 2018, 
organized by the International Breast Ultrasound School to re-evaluate the consensus recommendations.
Methods This study (1) evaluated how management recommendations of the first Zurich Consensus Conference of 2016 on 
B3 lesions had influenced daily practice and (2) reviewed current literature towards recommendations to biopsy.
Results In 2018, the consensus recommendations for management of B3 lesions remained almost unchanged: For flat epi-
thelial atypia (FEA), classical lobular neoplasia (LN), papillary lesions (PL) and radial scars (RS) diagnosed on core-needle 
biopsy (CNB) or vacuum-assisted biopsy (VAB), excision by VAB in preference to open surgery, and for atypical ductal 
hyperplasia (ADH) and phyllodes tumors (PT) diagnosed at VAB or CNB, first-line open surgical excision (OE) with follow-
up surveillance imaging for 5 years. Analyzing the Database of the Swiss Minimally Invasive Breast Biopsies (MIBB) with 
more than 30,000 procedures recorded, there was a significant increase in recommending more frequent surveillance of LN 
[65% in 2018 vs. 51% in 2016 (p = 0.004)], FEA (72% in 2018 vs. 62% in 2016 (p = 0.005)), and PL [(76% in 2018 vs. 70% 
in 2016 (p = 0.04)] diagnosed on VAB. A trend to more frequent surveillance was also noted also for RS [77% in 2018 vs. 
67% in 2016 (p = 0.07)].
Conclusions Minimally invasive management of B3 lesions (except ADH and PT) with VAB continues to be appropriate as 
an alternative to first-line OE in most cases, but with more frequent surveillance, especially for LN.
Keywords B3 lesions · Vacuum-assisted biopsy · Consensus · Breast · Uncertain malignant potential · Breast surgery
Introduction
Lesions of uncertain malignant potential in the breast (B3 
lesions) represent a heterogeneous group of abnormalities 
with an overall risk for malignancy of 9.9%–35.1% after 
total resection [1]. Historically open surgical excision has 
been recommended for all B3 lesions; however, over the 
last decade there has been a trend towards minimally inva-
sive breast biopsy or percutaneous excision using a vac-
uum-assisted device where larger volumes of tissue can be 
removed compared to core biopsy, equivalent to a small-
wide local excision while retaining the same diagnostic 
accuracy as open surgery [2], but with the obvious benefits 
of saving the patient a surgical procedure, and cost. Under-
estimates of malignancy in excised B3 lesions range up to 
35% and are associated primarily with increasing size of the 
lesion and the presence of atypia rather than the nature of the 
mammographic abnormality (e.g., calcification vs. mass or 
architectural distortion) [3]. Several studies also indicate that 
B3 lesions are predominantly upgraded to ductal carcinoma 
in situ (DCIS) and low-grade invasive tumors [1, 3–6].
The evidence base for the outcome and behavior of B3 
lesions in the literature is accruing. Management and prac-
tice vary greatly from country to country, although there 
is a trend universally for more conservative management 
as an alternative to open surgery. The 2016 recommenda-
tions from the first International Consensus Conference 
on B3 lesions [7] during the biannual International Breast 
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Ultrasound School (IBUS) course were well accepted by 
many breast units in different countries. The purpose of the 
second International Consensus Conference in 2018 was to 
re-evaluate how recommendations for the management and 
follow-up surveillance of B3 lesions in the breast had influ-
enced daily practice, review the most recent literature, and 
investigate the trend towards less open surgery and appropri-
ate surveillance.
Methodology
The second International Consensus Conference on lesions 
of uncertain malignant potential (B3) was held with inter-
national experts as part of the IBUS seminar in March 
2018. The meeting in March 2018 had 70 participants with 
an additional 19 multidisciplinary expert panel members 
(including all the aforementioned authors) comprising 
55% radiologists, and 45% other (including pathologists, 
surgeons, and gynecologists) with 68% having more than 
10 years’ experience in breast imaging. All participants were 
invited to vote on all recommendations and between 60 and 
80 (depending on the question asked) decided to vote.
A new analysis of the Swiss Minimally Invasive Breast 
Biopsy group (MIBB) Database was performed and pre-
sented (histology from 31,574 VABs). The Swiss MIBB 
group—a subgroup of the Swiss Society of Senology 
founded in 2007—has collected data for 11 years on each 
diagnostic or therapeutic VAB performed in Switzerland. 
To evaluate the impact of the B3 guidelines from the first 
International Consensus Conference in the management and 
surveillance of B3 lesions, the data were compared between 
2007 and 2015 and 2016–2017 using the Chi-squared test.
Recommendations for management of B3 breast lesions 
following histological diagnosis were either (i) surveillance 
(defined as 6 monthly or yearly mammography and/or ultra-
sound, depending on their imaging findings), (ii) VAB exci-
sion, or (iii) open excision.
Following presentations of each B3 lesion in detail 
with an update of the published literature since the first 
International Consensus Conference, three questions were 
asked in turn regarding each of the six B3 lesions [8]:
 Q1. If a core-needle biopsy (CNB) returned a B3 lesion on 
histology, should the lesion be excised?
 Q2. If so, should it be excised using vacuum-assisted 
biopsy (VAB) or open surgical excision (OE)?
 Q3. If the VAB returned a B3 lesion on histology and if the 
lesion was completely removed on imaging, is surveil-
lance acceptable or should a repeat VAB or OE be 
performed?
A panel discussion followed the voting and consensus 
recommendations were agreed for the management of each 
B3 lesion along with decisions on surveillance.
Results
Analysis of the MIBB database
From 2007 until 2017, a total of 31,574 VABs were 
entered in the database. 6,020 cases (19.1%) showed a B3 
lesion (4339 were pure and the other ones were combined 
B3 lesions).
Table 1 shows the pure B3 lesions together with the 
final histology in those which had a subsequent open sur-
gery and upgrade rates.
Table 2 shows recommendations made to the patients 
following VAB. Between 2016 and 2017, surveillance was 
recommended more frequently for all B3 lesions follow-
ing VAB, but this was only significant for the following 
lesions: FEA (72% vs. 61.5%: p = 0.005), LN (64.9% vs. 
51%; p = 0.004), and PLs (76% vs. 69.7%; p = 0.04).
Table 1  Pure B3 lesions 
together with the final histology 
in the cases, which had a 
subsequent open surgical 
excision (OE)
IC invasive cancer
Pure B3 
histol-
ogy
N With subsequent OE Total upgrade Upgrade to DCIS 
OR pleomorphic 
LN
Upgrade to IC No upgrade
ADH 943 591 (62.7%) 149 (25.2%) 119 (20.1%) 30 (5.1%) 408 (69.0%)
FEA 994 249 (25.1%) 40 (16.1%) 22 (8.8%) 18 (7.2%) 181 (72.7%)
LN 701 268 (38.2%) 68 (25.4%) 35 (13.1%) 33 (12.3%) 178 (66.4%)
PL 1251 272 (21.7%) 21 (7.7%) 16 (5.9%) 5 (1.8%) 217 (79.8%)
PT 35 4 (11.4%) 0 0 0 4 (100%)
RS 415 75 (18.1%) 6 (8%) 5 (6.7%) 1 (1.3%) 60 (80.0%)
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General recommendations of the panel members 
of the consensus conference
Acceptable rates for the risk of underestimation
In 2016, the panel of the first International Consensus Con-
ference on B3 lesions stated that every B3 lesion should 
be discussed at a multidisciplinary meeting (MDM). If an 
MDM makes the decision not to perform open surgery after 
a diagnosis of a B3 lesion following VAB, it means balanc-
ing risks (e.g., having to undergo a surgery under anesthesia 
which produces a scar) and benefits (e.g., not risking under-
estimating a lesion, which could be or develop towards an 
invasive cancer). Therefore in 2018, the question asked was: 
What is an acceptable underestimation rate for DCIS or IC?
69 participants gave answers for upgrade to IC: < 2.5%: 
36 (53%); < 5%: 23 (34%); < 7.5%: 8 (12%); and < 10%: 2 
(3%).
68 participants gave answers for upgrade to DCIS: < 5%: 
15 (22%); < 10%: 40 (59%); < 15%: 9 (13%); and < 20%: 4 
(6%). Therefore, overall underestimation rates for the major-
ity of the panel members were that it should not exceed 5% 
for IC and 10% for DCIS.
Reasons for recommending an open biopsy instead 
of surveillance
The panel also discussed which circumstances would argue 
for performing an open biopsy instead of surveillance only. 
Discrepancy between histology and imaging was by far the 
most important factor. For example, if a solid lesion and 
not only microcalcifications are seen, then histology should 
correspond to this finding. Further strong arguments for per-
forming a subsequent open biopsy or a repeat VAB were a 
residual lesion and lesion size. The larger a lesion is, the 
more likely an open biopsy should be recommended. For an 
ultrasound-guided VAB, the size should usually not exceed 
2.5 cm. Elevated personal risk, the presence of a solid lesion 
on ultrasound, associated calcifications within the lesion, 
and absence of calcifications within the lesion were also 
considered.
Recent literature
Recent manuscripts dealing with B3 lesions were selected 
for presentation and discussion at the conference. Many of 
the papers document upgrade rates in following open exci-
sion and the risk of developing a cancer during the years 
following a diagnosis of a B3 lesion. In some of the manu-
scripts, CNB and VAB were not well differentiated. CNB, 
often also called microbiopsy, should be used for CNB 
performed with devices smaller or equal to 14G. The term 
VAB, often called macrobiopsy, would therefore be reserved 
for larger needle devices (typically 7 to 11G). Since upgrade 
rates depend on the amount of tissue, which is available for 
the pathologist for examination, this distinction is important.
Atypical ductal hyperplasia (ADH)
Histological criteria of ADH
ADH is a low-grade neoplastic intraductal proliferation. The 
histological criteria of ADH include quantitative features of 
low-grade atypia as monomorphic nuclei with clear mem-
branous borders and secondary intraluminal adenoid archi-
tecture. As quantitative features, restriction to one terminal 
ductal-lobular unit (TDLU) is usually ≤ 2 mm in maximal 
extension, whereas the histological as immunophenotypi-
cal features of an ADH lesion are the same as at low-grade 
DCIS. Intraductal ADH cell proliferations are negative for 
high molecular weight cytokeratins and strongly and dif-
fusely positive for estrogen receptors in the same pattern as 
seem at low-grade DCIS. The differential diagnosis between 
ADH and DCIS is based on size only. Therefore, a low-grade 
in situ neoplastic lesion with qualitative features of ADH 
cannot definitely be separated from a part of a larger low-
grade DCIS based on findings in minimal invasive breast 
Table 2  Pure B3 lesions with the recommendations after the VAB comparing two time periods 2016–2017 versus 2007–2015
*Significant result
OE Open surgical excision
Pure B3 
histology
N MIBBs OE Recommended Surveillance recommended Recommendation of surveillance dif-
ference between 2 time periods in %2007–2015 2016–2017 2007–2015 2016–2017 2007–2015 2016–2017
ADH 779 160 549 (70.5%) 113 (70.6%) 181 (23.2%) 41 (25.6%) 2.4 (p = 0.52)
FEA 786 207 247 (31.4%) 52 (25.1%) 483 (61.5%) 149 (72%) 10.5* (p = 0.005)
LN 561 131 236 (42.1%) 42 (32.1%) 286 (51%) 85 (64.9%) 13.9* (p = 0.004)
PL 961 288 217 (22.6%) 57 (19.8%) 670 (69.7%) 219 (76%) 6.3* (p = 0.04)
PT 22 13 8 (36%) 3 (23%) 14 (64%) 9 (69%) 5.6 (p = 0.74)
RS 316 99 80 (25.3%) 18 (18.2%) 212 (67.1%) 76 (76.8%) 9.7 (p = 0.07)
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biopsy (CNB or VAB) alone. The European Working Group 
on Breast Screening Pathology recommends that it should 
always be kept in mind that such proliferations at a biopsy 
may represent the periphery of a more established lesion of 
DCIS [9].
Underestimation risk associated with ADH at VAB
The dilemma in decision making on management of an 
ADH-like lesion at MIBB is the uncertainty whether it rep-
resents a part of a larger DCIS or is an isolated lesion. There 
is only limited information on histological, imaging, and 
clinical factors, which can reliably predict the answer. These 
include lesion size and number of ADH foci in biopsy spec-
imens, radiological features, needle type, and association 
with calcification and individual cell necrosis. Until now, 
none of these features can reliably exclude an upgrade in the 
surgical specimen. However, risk factors for underestimation 
of malignancy include multifocality with more than 2 foci 
of ADH on CNB, and associated individual cell necrosis, 
this latter might be suggestive but definitely not affirma-
tively diagnostic of a low-grade DCIS. In addition, lack of 
radiological-pathological correlation as lack of calcification 
in MIBB specimens on VAB performed for mammographi-
cally suspicious calcifications as well as ADH-like lesions 
as only histopathological finding in biopsies taken for mass 
lesions on imaging. Conflicting results of several studies 
analyzing the risk factors of synchronous malignancy in 
MIBB with ADH published in recent years as the large range 
of their underestimation rates (2%–50%), as summarized in 
Table 3, seems to be depending on the type of biopsy per-
formed (CNB or VAB), age (> 50 years), and on associated 
microcalcification on imaging. But above all, upgrade rates 
are generally higher in biopsies without any pathological 
correlation to the target lesion in imaging. Table 3 summa-
rizes the literature update on ADH since 2015.
Since upgrade rates in so-called lower-risk subgroups 
exceed the defined acceptable limits for underestimation 
(10% for DCIS and 5% for IC), OE is recommended in gen-
eral even if the lesion seems to be completely excised by 
VAB. Surveillance instead of OE might be appropriate in 
special situations (especially in older age) since most of the 
IC that develop after ADH are small low-grade cancers. Sur-
veillance is also necessary after OE because such patients 
are at a higher risk of developing cancer also distant from 
the excised ADH lesion and also in the contralateral breast.
Voting
If a CNB returned ADH on histology,
100% of the participants thought the lesion should 
be excised. 21% thought therapeutic VAB excision was 
acceptable and 74% thought therapeutic open surgical exci-
sion should be performed. 5% were undecided.
If a VAB returned ADH on histology,
51% of the participants thought that therapeutic open sur-
gical excision should be performed and 42% thought that 
surveillance was adequate (Table 9).
Consensus recommendation of the panel
A lesion containing ADH diagnosed by CNB or VAB 
should undergo open surgical excision. Surveillance can 
be justified only in special situations after discussion at 
the MDM (Table 10).
Flat epithelial atypia (FEA)
Histological criteria of FEA
FEA is a low-grade neoplastic lesion consisting of a few 
layers of neoplastic columnar type cells with low-grade 
(monomorphic) atypia without any secondary architec-
ture (flat architecture). The immunophenotype of a FEA 
lesion is identical to that of a low-grade DCIS, which is 
negative for basal cytokeratins and positive for estrogen 
receptors. On histology, there is a classical association 
with low-grade or highly differentiated lesions as highly 
differentiated invasive carcinoma, ADH/DCIS, and to the 
other B3 lesions as classical LN. There are often associ-
ated calcifications and, therefore FEA is sometimes the 
only biopsy target at mammography.
Biology of FEA
FEA seems to be associated with a very slight increased 
breast cancer risk (1–2 times). Underestimation of risk is 
associated with ADH at MIBB.
Lesions found after FEA on breast core-needle CNB and 
VAB are mainly ADH and low-grade DCIS, while invasive 
carcinoma (in most instances highly differentiated) can 
occur but less frequent. Recommendation of current guide-
lines is increasingly in favor of surveillance if the lesion is 
small and the radiological findings were completely removed 
by CNB or VAB. Table 4 summarizes the literature update 
on FEA since 2015.
Voting
If a CNB returned FEA on histology,
65% of the participants thought the lesion should be 
excised. 75% thought therapeutic VAB excision was 
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Table 3  Summary of the recent literature on ADH since 2015
Author and year Number of patients analyzed or 
type of publication if no patients 
have been analyzed (e.g., review or 
comment)
Findings Conclusions
Ahn et al. 2016 [10] n = 103
Upgrade
Underestimation rates
FEA (5.9%)
FEA + ADH (44.4%)
ADH 27.3%
Recommend OE especially if calcifi-
cation is present
Badan et al. 2016 [11] n = 40
Upgrade
Underestimation rate
ADH in CNB (50%)
ADH in VAB (25%)
Recommend OE
Co et al. 2018 [12] n = 104 ADH in CNB (41%) Suspicious mammogram correlates 
with upgrade
Collins et al. 2016 [13] Association between extent of 
ADH/LN and BC risk
1–2 foci ADH (OR 3.5)
1–2 foci LN (OR 5.2)
≥ 3 foci ADH (OR 2.7)
≥ 3 foci LN (OR 8.0)
No influence of extent of ADH or LN 
on BC risk
Degnim et al. 2016 [14] Association between extent of ADH 
/LN and BC risk
1–2 foci ADH (RR:2.65)
2 foci ADH (RR: 5.19)
≥ 3 foci ADH (RR 8.94)
1–2 foci LN (RR:2.58)
2 foci LN (RR: 3.49)
≥ 3 foci LN (RR 4.97)
BC risk increases with ADH/LN 
extension
p < 0.001
Donaldson et al. 2018 [15] n = 393
Upgrade
ADH/LN on CNB No upgrade
Khoury et al. 2016 [16] n = 100
Upgrade
Underestimation rate
ADH in VAB (15%)
Extension and nb of positive cores 
correlate with upgrade
Latronico et al. 2018 [17] Upgrade (n = 45) and long-term 
follow-up (n = 12)
Upgrade after ADH 45%
BC (8%)
Recommend OE
Menen et al. 2017 [18] n = 175
Follow-up after/wo surgery
BC 12% (after surgery)
BC 5.6% (only follow-up)
Contralateral BC only after surgery
Prior history of breast cancer was the 
only variable associated with subse-
quent breast cancer events (hazard 
ratio 12.53)
Menes et al. 2017 [19] BC risk after ADH in CNB 
(n = 1727)
OE (n = 635)
10-year cumulative BC risk
2.6% (CNB)
5.7% (OE)
BC risk after ADH diagnosis is 
higher
Mesurolle et al. 2014 [20] n = 50
Upgrade ADH in CNB
Underestimation rate
ADH in CNB (56%)
OE recommended
Pena et al. 2017 [21] n = 399
Low BC risk after
ADH in CNB
Underestimation rate
ADH in CNB (16%)
Low BC risk
ADH in CNB (4–9%)
Low BC risk if
(1) lack of necrosis and
(2) 1–2 foci or ≥ 3 foci with ≥ 90% 
removal
Renshaw and Gould, 2016 [4] Upgrade and
Long-term clinical follow-up
175 ADH on CNB
Underestimation rate
ADH in CNB (30.3%)
BC after surgery (11.5%)
Immediate BC risk is higher for ADH 
than LN
Long-term BC risk is higher for LN 
than ADH
Yu et al. 2015 [22] Upgrade
ADH in CNB (83)
Underestimation rate
ADH in CNB 9.5%
Age, associated mass, and calcifica-
tion distribution are independent 
factors for upgrade
Rageth et al. (data presented 
at the conference, but not 
yet published)
Upgrade and histological criteria
207 ADH cases
(56 CNBs and 151 VABs)
Underestimation rate
ADH in CNB 57%
ADH in VAB 33%
Factors in upgrade
(1) Method (CNB vs. VAB)
(2) The presence of multifocality
(3) Absence of associated calcifica-
tion
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acceptable and 22% thought therapeutic open surgical exci-
sion should be performed.
If a VAB returned FEA on histology,
3% of the participants thought that therapeutic open sur-
gical excision should be performed and 97% thought that 
surveillance was adequate (Table 9).
Consensus recommendation of the panel
A lesion containing FEA which is visible on imaging should 
undergo excision with VAB. Thereafter surveillance is justi-
fied (Table 10).
Classical lobular neoplasia
Histological criteria
Lobular neoplasia (LN) includes a large spectrum and con-
tinuum of atypical intralobular proliferations of the TDLs 
of the breast, consisting of non-cohesive proliferating cells. 
Under the term “Classical Lobular Neoplasia,” the consensus 
conference discussed the two lesions defined by the WHO 
classification as classical lobular carcinoma in situ (LCIS) 
and atypical lobular hyperplasia (ALH), both of which rep-
resent the large majority of lobular neoplasia. ALH/LCIS are 
characterized by non-cohesive proliferations of atypical type 
A and/or B epithelial cells with mild-to-moderate nuclear 
atypia in about 85% of cases [33]. In case of LCIS, these 
cells expand more than 50% of the acini in a terminal duct-
lobular unit (TDLU), while in ALH this affects less than 
50%. When diagnosed on minimal invasive biopsy (VAB), 
these lesions are reported as B3 by the pathologist. In case 
of diagnostic difficulty in the histological diagnosis, the use 
of a combined immunohistochemistry with E-Cadherin and 
Catenin p120 is useful to rule out morphological differential 
diagnoses especially as solid DCIS.
In contrast, the rare morphologic variants including pleo-
morphic LN which demonstrates marked nuclear pleomor-
phism equivalent to that of high-grade ductal carcinoma 
in situ (DCIS), with or without apocrine features. A florid 
LN along with marked distention of TDLUs or ducts, often 
with accompanying mass formation and comedo type necro-
sis, are reported as B5a as DCIS and are not discussed as LN 
in this consensus report. The underlying rationale is that in 
contrast to LCIS and ALH, 25–60% of cases with LN (B5a 
category) variants on CNB/VAB are found to upgrade to 
carcinoma on excision [34–36]. The reproducibility of all 
LIN ALH versus LCIS is poor, the prognostic significance 
between LIN1,2 is not supported by evidence, so it is not 
endorsed by current European guidelines (AGO [37]). It is 
a simplified and practical way to categorize these lesions as 
B3 (e.g., as classical LN) and B5a (as pleomorphic or florid 
LN) especially on CNB and VAB.
Biological behavior
ALH/LCIS has to be considered as both, a risk factor and a 
non-obligate precursor of invasive breast carcinoma confer-
ring an 8 to 10 times relative risk compared to the general 
population [38, 39]. The absolute risk of either lobular or 
ductal breast cancer is in the range of 1–2% per year with a 
cumulative long-term rate of more than 20% at 15 years and 
35% at 35 years [39, 40]. The risk is bilateral with ipsilateral 
predominance [41, 42].
Until now, no single histopathological or clinical factor 
alone has been identified which could link the development 
of breast cancer to a histological diagnosis of classical LN.
Risk of breast cancer at CNB/VAB
The management of patients with classic LN when diag-
nosed on MIBB (CNB/VAB) has been controversial due to 
a wide range (0–60%) of reported upgrade rates to DCIS or 
invasive carcinoma on excision. Those rates result above 
all from disregarding radiological–pathological correlation 
[43–46]. LCIS and ALH are infrequently seen as the sole 
finding in CNB or VAB accounting for 0.5–2.9% of biopsies 
taken for histologic assessment of mammography-detected 
lesions. Therefore, recent studies of classic LCIS and ALH 
as incidental finding in cases where a different benign patho-
logical lesion in the same biopsy has been proved to repre-
sent the correlation to the radiological biopsy target with 
concordant imaging findings report very low (~ 1–4%) exci-
sional upgrade rates of classic LCIS and ALH to carcinoma. 
Regarding ALH, the largest study showed a relative risk of 
8.0 for women with 3 or more foci of ALH compared to 3 
or 5 for women with 1 or 2 foci, respectively. The upgrade 
rates for classical LCIS are generally higher (13% to 18%) 
when LCIS represented the radiologic target as calcification 
and still higher for mass lesions and calcification on imaging 
with radio-pathological discordance [47–49]. Current (AGO 
[37]) guidelines in favor of surgical management of classi-
cal LN include the presence of another B3 lesion, another 
lesion indicative for excision alone, the presence of a visible 
or mass lesion or any discordant lesions between histology 
and imaging (AGO [37]). Table 5 summarizes the literature 
update on classical LN in CNB/VAB since 2015.
Voting
If a CNB returned Classical LN on histology,
69% of the participants thought the lesion should be 
excised. 50% thought therapeutic VAB excision was 
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acceptable and 41% thought therapeutic open surgical exci-
sion should be performed.
If a VAB returned Classical LN on histology,
12% of the participants thought that therapeutic open sur-
gical excision should be performed and 84% thought that 
surveillance was adequate (Table 9).
Consensus recommendation of the panel
A lesion containing classical LN, which is visible on imag-
ing should undergo excision with VAB. Thereafter surveil-
lance is justified if there is no pathological–radiological 
discordance and no residual lesion.
In contrast, morphologic variants of LN (LIN 3, pleo-
morphic LCIS, and florid LCIS), which are reported as B5a 
lesions should undergo OE (Table 10).
Papillary lesions
Histology and clinical presentation of PL
On imaging, intraductal papillomas vary in size and in pres-
entation showing a spectrum of mass lesions to cystic and 
calcified lesions. Histology demonstrates a papillary prolif-
eration as the basis with a central fibrovascular core contain-
ing ductal and myoepithelial cells. In case of any histological 
uncertainty regarding the presence of myoepithelial cells, 
the use of immunohistochemistry (p 63, basal cytokeratins, 
and estrogen receptors) is helpful. In the current WHO clas-
sification of breast tumors, papillary lesions are divided into 
(a) papillomas, (b) papillomas with atypia (ADH or classical 
LN), both belonging to the B3 category at MIBB (small soli-
tary papillomas (< 2 mm) can be categorized as B2 lesion, 
if the lesion is completely surrounded by a duct structure) 
and to (c) papillomas with DCIS or papillomas completely 
involved by more extended DCIS (encapsulated papillary 
carcinoma), and finally (d) solid papillary carcinoma belong-
ing to B4 or B5a category. Table 6 summarizes the literature 
update on B3 papillary lesions since 2015.
Voting
If a CNB returned PL on histology,
76.5% of the participants thought the lesion should be 
excised. 71% thought therapeutic VAB excision was accept-
able and 23% thought therapeutic open surgical excision 
should be performed.
If a VAB returned PL on histology,
none of the participants (1 abstained) thought that thera-
peutic open surgical excision should be performed and 98% 
thought that surveillance was adequate (Table 9).
Consensus recommendation of the panel
A PL lesion, which is visible on imaging should undergo 
excision with VAB. Larger lesions which cannot be com-
pletely removed by VAB need open excision. Thereafter 
surveillance is justified (Table 10).
Phyllodes tumors (PT)
Histological criteria and biological behavior of PT
PTs are rare and consist of around 1–2‰ of all breast biop-
sies. PTs are biphasic fibroepithelial tumors varying from 
benign to borderline and malignant diagnostic variants. The 
latest WHO classification of breast tumors allows three cat-
egories depending on the number of stromal mitoses, stromal 
atypia, and stromal overgrowth. In some cases, the distinction 
between a benign cellular fibroadenoma and a benign phyl-
lodes tumors remains despite histological diagnostic criteria 
problematic. Therefore, the WHO classification recommends 
the diagnosis of a benign fibroepithelial tumor (also catego-
rized as B3 category) in unclear cases. Benign and borderline 
phyllodes tumors are B3 lesions, a malignant PT is a B5b 
lesion. B3 forms, particularly the benign forms of PT, are the 
most common, only up to 20% of all PT tumors are borderline 
or malignant. Risk for local recurrence at benign PT is around 
10–20% and reaches up to 30% at the borderline or malignant 
forms. Metastatic potential depends on the form, being the 
highest (15–20%) at the malignant forms. Table 7 summarizes 
the literature update on B3 phyllodes tumors since 2015.
Voting
If a CNB returned PT on histology,
98% of the participants thought the lesion should be 
excised. 22% thought therapeutic VAB excision was accept-
able and 72% thought therapeutic open surgical excision 
should be performed.
If a VAB returned PT on histology,
8% of the participants thought that therapeutic open sur-
gical excision should be performed and 88% thought that 
surveillance was adequate (Table 9).
Consensus recommendation of the panel
A PT lesion, which is found by CNB, should undergo open 
surgical excision with clear margins. If accidentally found by 
VAB without any corresponding imaging finding, surveillance 
of a benign PT is justified, while borderline and malignant 
PTs require re-excision to obtain clear margins (Table 10).
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Table 6  Summary of the recent literature on PL since 2015
Author and year Number of patients analyzed or type 
of publication if no patients have been 
analyzed (e.g., review or comment)
Findings Conclusions
Ahn et al. 2018 [58] n = 520 PL in CNB
250 with OE
Upgrade
Upgrade in 17 of 250 cases (6.8%) Factors in upgrade
-Bloody nipple charge
-Size on imaging ≥ 15 mm
-BI-RADS≥ 4b
-Peripheral location
-Palpability
Armes et al. 2017 [59] n = 103 PL on CNB
Upgrade
Upgrade
Overall in 30%
With atypia in 72%
Without atypia in 7%
Conservative management for those 
without atypia, including those without 
atypia in which the papillary lesion was 
found incidental to microcalcification in 
an adjacent benign lesion
Bianchi et al. 2015 [60] Upgrade in PL lesions
46 Cases with atypia
68 Cases without atypia
Upgrade in
47.8% (22/46) cases with atypia
13.2% (9/68) without atypia
Underestimation rate in PL without atypia 
is lower
Khan et al. 2017 [61] n = 259 PL on CNB
Upgrade in OE (n = 147)
Upgrade
7% without atypia (8/107)
33% with atypia (13/40)
Higher upgrade in PL with atypia
Kim et al. 2016 [62] n = 230 PL in CNB
Upgrade
In VAB (n = 86)
In OE (n = 144)
Upgrade in 2.6% (6/230) Upgrade in
BI-RADS 3-4a :1.4% resp. 1.8%
BI-RADS 4b-5: 13% resp. 50%
No association with age and size lesion
Ko et al. 2017 [63] n = 346 PL in CNB
Upgrade
In VAB (n = 211)
In OE (n = 135)
Upgrade
Overall in 2.3%
If size < 1cm: 0.9%
Size of PL correlates with upgrade
Close follow-up with ultrasound instead 
of excision
Moon et al. 2016 [64] n = 65 PL in CNB
Upgrade
In VAB (n = 12)
In OE (n = 53)
Upgrade
In OE in 9% (5/53)
In VAB 8% (1/12)
No recommendation
Niinikoski et al. 2018 [65] n = 80 PL in CNB Small PL in selected patients-OE can be 
avoided
Pareja et al.. 2016 [66] Upgrade in OE (n = 171) after PL With-
out atypia
In CNB
Upgrade
In OE 2.3% (4/171)
Regardless of size, observation is 
appropriate at radiologic–pathologic 
concordant CNB
Seely et al. 2017 [67] n = 107 PL in OE
Upgrade after
VAB (n = 60)
CNB (n = 47)
Upgrade in OE
After VAB in 1.6% (1/60)
After CNB in 8.5% (4/47)
Higher upgrade in OE if PL is diagnosed 
on CNB
Tatarian et al. 2016 [68] n = 16 PL in CNB
Upgrade in OE
Upgrade in OE
In 2/16 cases (12.5%)
Surgical excision should be considered in 
patients with benign papillomas
Tran et al. 2017 [69] n = 43 PL in CNB
Upgrade in OE
Upgrade in OE
In 1/43 cases (2%)
Low-upgrade rate in OE
Wyss et al. 2014 [70] n = 156 PL in CNB
Upgrade
In VAB (n = 135) and
Follow-up (n = 21)
(Median 3.5 years)
Upgrade after follow-up
1.2% (2/156)
VAB is recommended as the method of 
choice for removal of PL
Yamaguchi et al. 2015 [71] n = 142 PL
Follow-up imaging
After VAB (n = 125)
After CNB (n = 17)
Upgrade in OE (n = 17)
4/17
Discordant lesions should undergo OE
Yang et al. 2018 [72] n = 116 PL
(On CNB or VAB)
10 mm or smaller
OE n = 74
Surveillance n = 42
Overall upgrade 11% (13/116)
Upgrade after VAB (0%)
Upgrade after CNB (16.5%)
Higher upgrade in OE
-After CNB
-Older age
-Pl with atypia
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Radial scar
Histological features of RS
Two papers published almost at the same time described the 
same lesion naming that was named radial scar by Hamperl 
[79] and scleroelastotic lesion by Eusebi et al. [80]. More 
recently, the definition of complex sclerosing lesion (CSL) 
has been proposed. RS is characterized by a central area 
mimicking a scar, containing one to several ducts showing 
obliterative mastopathy, and surrounded by elastic fibers. In 
addition, other ducts converge into the scar-like area in a stel-
late fashion. The epithelium lining the latter ducts may show 
a great variety of changes, the most frequent being benign 
epitheliosis (usual ductal hyperplasia). The central scar-like 
area together with stellate appearance of the outer ducts eas-
ily mimics an invasive carcinoma, both on radiological and 
histological grounds. RS can be detected during screening 
Table 7  Summary of the recent literature on PT since 2015
Author and year Number of patients analyzed or 
type of publication if no patients 
have been analyzed (e.g., review 
or comment)
Findings Conclusions
Co et al. 2017 [73] n = 465 PT
281 (59.9%)benign
124 (26.4%) Borderline 64 
(13.6%) malignant
384 (82%) Breast-conserving 
surgery (BCS)
84 (18%) Patients with mastec-
tomy
Median follow-up 85 months
Risk factors for local recurrence
(1) Positive margins (p < 0.001)
(2) BCS (p < 0.001)
Risk factors for local metastases
(1) Large tumor size (p = 0.008)
(2) Malignant component 
(p < 0.001)
Disease-free survival
99.6% (benign)
100% (borderline)
90.6% (malignant)
Kim et al. 2017 [73] n = 146 PT (benign)
Surgery (n = 126)
US-VAB (n = 20)
Three cases (2.1%, 3/146) had 
recurrence and all were in the 
surgery group (2.4%, 3/126)
Clinical follow-up rather than fur-
ther surgery at benign phyllodes 
tumor diagnosed at US-VAE, if 
there is no residual lesion at US
Ouyang et al. 2016 [74] n = 225 benign PT
Surgery (n = 117)
VAB (n = 108)
5-year cumulative RFS
81.6 (VAB)
8.7% (surgery)
(p = 0.11)
No difference in DFS between OE 
and VAB removal
Sevinc et al. 2018 [75] n = 122 PT (benign and border-
line)
All underwent surgical excision
No local recurrence occurred in 
any group
Positive surgical margins in 43 
(35%)
Margins ≥ 10 mm in
16 patients (13%)
Margins 2–10 mm in
48 patients (40%)
Margins ≤ 1 mm in
15 patients (12%)
Positive resection margins did not 
influence local recurrence
Shaaban and Barthelmes 2017 
[76]
n = 1702 PT
Literature review (12 studies)
Margin assessment
1 mm distance
10 mm distance
Focal margin involvement
No difference in recurrence rates 
between a 1- and a 10-mm 
margin
The recurrence rate increases if 
there is focal margin involve-
ment. 1 mm is acceptable for 
benign PT
Youk et al. 2015 [77] n = 41 PT (benign)
OE after VAB (n = 27)
2 Years follow-up with US 
(n = 14)
Upgrade
2/23 (8.7%) to malignant PT
Residual tumor
15/27 (55%)(at VAB site)
0/14 (0%)(US follow-up)
PTs diagnosed after US-VAB 
should be surgically excised
Zhou et al. 2016 [78] Sensitivity of definitive PT cat-
egory in CNB versus OE
The sensitivity of CNB
4.9% (2/41) benign
4.2% (3/71) borderline
25.0% (4/16) malignant
CNB in PT category has low 
sensitivity
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mammography and now even more often by tomosynthe-
sis, therefore sampled by CNB or by VAB. There is general 
agreement that RS alone is a benign lesion, but RS can be 
occasionally associated with carcinoma. When RS is associ-
ated to atypia (such as flat epithelial atypia (FEA), atypical 
ductal (ADH), or lobular neoplasia (classical LN)), manage-
ment can the same as recommended in cases of atypia alone. 
Management is more controversial in cases without atypi-
cal lesions. In these cases, upgrade of cancers is associated 
with architectural distortions and larger masses (≥ 10 mm), 
calcifications, and older age [69, 71]. The recently published 
data suggest that in cases of RS diagnosed using CNB or 
VAB, it must be taken into consideration that (a) accurate 
and detailed radiological–pathological correlations must 
be obtained; (b) lesions < 10 mm have lower rate of cancer 
upgrading; (c) histology is vital in the evaluation of pres-
ence or absence of atypical features within the lesion. Table 8 
summarizes the literature update on radial scar since 2015.
Voting
If a CNB returned RS/CSL on histology,
85% of the participants thought the lesion should be 
excised. 72% thought therapeutic VAB excision was accept-
able and 26% thought therapeutic open surgical excision 
should be performed.
If a VAB returned RS/CSL on histology,
Table 8  Summary of the recent literature on RS since 2015
Author and year Number of patients analyzed or type 
of publication if no patients have been 
analyzed (e.g., review or comment)
Findings Conclusions
Donaldson et al. 2016 [81] n = 37 RS
upgrade in OE
Upgrade in OE
31/37 (84%, benign)
2/37 (5%, ADH)
3/37 (8%, LN classic)
1/37 (3%, FEA)
Low upgrade in OE at isolated radial scar 
on preoperative CNB/VAB
Ferreira et al. 2017 [82] n = 113 RS
25 (CNB)
88 (VAB)
Upgrade in OE
22/113 (20%)
Risk for upgrade
-Type of biopsy (CNB or VAB)
-Presence of atypia
-Presence of calcifications
-Nr. of biopsy fragments
At VAB, the risk of upgrade and malig-
nancy is significantly decreased and 
so the indication for excisional biopsy 
seems not to be so imperative
Hou et al. 2016 [83] n = 113 RS
n = 81 without atypia
n = 32 with atypia
Upgrade in OE
No upgrade in RS without atypia
RS without atypia on VAB has a very low 
risk for upgrade
Kalife et al. 2016 [84] n = 100 RS on CNB
41 cases had OE
Upgrade in OE
4/41 (10%) cases with atypia
No cases to malignancy
Close imaging follow-up is adequate for 
patients with RS/RSL without associated 
atypia malignancy on CNB
Kim et al. 2016 [85] n = 88 RS on CNB/VAB
63 (72%) had OE
Upgrade in OE
1/63 (1.5%)
Isolated radial scar may not warrant routine 
surgical excision given relatively low 
cancer upgrade rates
Leong et al. 2016 [86] n = 219 RS on CNB
161 (74%) had OE
Upgrade in OE
1/161 (0.6%)
Surgical excision is unnecessary if radial 
scar is found at CNB without an associ-
ated proliferative lesion but is still indi-
cated when radial scar is associated with 
atypical ductal hyperplasia or lobular 
neoplasia
Li et al. 2016 [87] n = 403 pure RS on CNB
220 (54.6%) had OE
Upgrade in OE
2/220 (0.9%) malignancy
44/220 (20%) ADH
13/220 (5.9%) classical LN
Conservative follow-up with imaging 
rather than surgical excisions may be 
more appropriate for isolated RS
Miller et al. 2014 [88] n = 131 pure RS on CNB
All had OE
Upgrade in OE
2 /131 (1.5%) malignancy
22/131 (17%) high-risk B3 lesion
Excision of RS to rule out associated inva-
sive carcinoma is not warranted, given a 
1% rate of upgrade at excision
Nassar et al. 2015 [89] n = 38 RS
Upgrade in OE
Upgrade in OE
4/38 (10%) malignancy
7/38 (18%) high-risk lesions 
(1xADH, 6xclassical LN)
Open excision for RS larger than 1.0 cm 
with worrisome radiographic findings or 
with radiologic and pathologic discord-
ance is recommended
Park et al. 2016 [90] n = 10 pure RS on CNB
Upgrade in OE
No upgrade in OE Pure RS on CNB may not need OE
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2% of the participants thought that therapeutic open sur-
gical excision should be performed and 98% thought that 
surveillance was adequate (Table 9).
Consensus recommendation of the panel
A RS/CSL lesion, which is visible on imaging should 
undergo therapeutic excision with VAB. Thereafter surveil-
lance is justified (Table 10).
Tables 9 and 10 show the summaries of the votings and 
the recommendations for each B3 lesion.
Discussion
The panel agreed that underestimation rates should be below 
5% for IC and below 10% for DCIS. If a certain B3 lesion 
shows an upgrade rate of more than 10%, in general surveil-
lance was not recommended. Computer-aided decision mak-
ing would be of interest. Bahl et al. [91] show the potential 
of machine learning methodology in the field of high-risk 
breast lesions predicting the risk of upgrade (editorial by 
Shaffer [92]).
Other recommendations [93, 94] favor recommendations 
from the consensus meetings. They do not explicitly propose 
VAB as we do, probably due to the fact, that VAB is not so 
well established in other countries yet.
The 2018 recommendations confirm largely the 2016 
recommendations. Results presented in the recent literature 
confirm the 2016 recommendations for surveillance after a 
B3 lesion diagnosed by VAB or CNB, especially for FEA, 
RS, PL, and PT. Upgrade rates are high in ADH and in LN 
which are not only focal or an incidental finding especially 
if pathological–radiological concordance is not given. LN 
lesions with pleomorphic, extended features, and LN with 
necrosis should be reported as B5a lesions and should 
undergo OE as DCIS. Our recommendations for ADH are 
slightly less liberal in 2018 than in 2016 and tend more 
towards OE.
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